Roche to Offer Flu Pill in U.S. for Just $50 — Bypassing Channels

Swiss pharma giant Roche is launching direct-to-consumer U.S. sales of its influenza treatment Xofluza priced at $50 per course, a steep 70% discount on its list price.

The offering — available to both insured and uninsured patients — will be sold via same-day delivery services like Alto Pharmacy, Amazon Pharmacy, and Mark Cuban’s Cost Plus Drug Company, but not through major chains like CVS.

The move comes amid mounting pressure from the Trump administration to lower U.S. drug costs. While Roche says the program won’t initially be part of the upcoming TrumpRx platform, it views the launch as supporting the administration’s push.

Roche already offers a coupon for Xofluza that lowers out-of-pocket costs to $35 for some patients. The drug treats influenza in patients aged 12 and older and must be taken within 48 hours of symptom onset.

Analysts expect Xofluza sales to reach $340 million in 2025 under this broader access strategy.